Vertex said its November 30th PDUFA date for povitacicept in IgA nephropathy is on track, with high visibility and confidence. Interim phase three data from the amplitude study of anaxiplin in APOL1-mediated kidney disease are expected early in 2027. Management has talked about $500 million plus in revenue from non-CF products.
VRTX · Vertex Pharmaceuticals Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Vertex Pharmaceuticals Inc reported Q3 2026 total revenues of $3.4 billion versus $3.1 billion in Q3 2025. The Crinetics Acquisition added compensation and transaction expenses, while cash, cash equivalents and marketable securities fell to $9.8 billion on September 30, 2026.
Vertex reported third-quarter total revenue up 12% year-over-year and raised full-year revenue guidance to $13.15 to $13.25 billion, including Krenetics. Non-GAAP operating expense guidance was revised to approximately $6 billion.
Vertex Pharmaceuticals reported third quarter 2026 revenue of $3.44 billion, up 12%, and raised full year 2026 revenue guidance to $13.15 billion to $13.25 billion. Povetacicept has an FDA action date of November 30, 2026.
Vertex Pharmaceuticals reported that povitacicept achieved a 52% proteinuria reduction at 36 weeks in IgA nephropathy, with a November 30th PDUFA date, while the fully enrolled Amplitude trial of 522 patients is expected to report interim results early next year.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 3, 2026TL;DR. Vertex raised full-year 2026 revenue guidance to $13.1–$13.2 billion on 12% Q2 revenue growth, while CASGEVY surged 78% sequentially with a record pediatric FDA approval and JOURNAVX quadrupled year-over-year on expanding payer coverage.
- + Raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion
- + CASGEVY Q2 revenue grew 78% sequentially to $76 million with FDA pediatric approval in record 53 days
- + Povetacicept BLA accepted with November 30 PDUFA, supported by best-in-class Phase 3 RAINIER results
- + Announced $8.8B Crinetics acquisition adding a fifth pillar in rare endocrine with ~$5B peak sales opportunity
- − Non-GAAP operating expenses now expected at high end of $5.65–$5.75B range due to commercial investment in launches
- − Gross margin expected to step down in second half due to product mix and manufacturing investments
- − JOURNAVX gross-to-net normalization delayed to first half of 2027 as PSP utilization exceeds forecast
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ALYFTREK | $705.8M | FY2026 Q3 | +185.7% |
|
|
|||
| CASGEVY | $99.2M | FY2026 Q3 | +487.0% |
|
|
|||
| JOURNAVX | $58.3M | FY2026 Q3 | +197.4% |
|
|
|||
| Other CF product revenues | $130.5M | FY2026 Q3 | -6.3% |
|
|
|||
| Total CF product revenues, net | $3.27B | FY2026 Q3 | +7.7% |
|
|
|||
| TRIKAFTA/KAFTRIO | $2.44B | FY2026 Q3 | -8.2% |
|
|
|||
| Combined non-GAAP R&D, AIPR&D and SG&A expenses non-GAAP | $4.25B | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP effective tax rate non-GAAP | 19.6% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP net income non-GAAP | $3.57B | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP operating income non-GAAP | $4.15B | Nine Months Ended September 30, 2026 | — |
|
|
|||
| prescriptions filled for JOURNAVX across the hospital and retail settings | 750,000 | third quarter | — |
|
|
|||
| target specialty endocrinologists are prescribing PALSONIFY | 500 | end of the third quarter of 2026 | — |
| total number of countries where ALYFTREK is reimbursed | 32 | third quarter of 2026 | — |
| Shares repurchased | 1,033,652 | the three months ended June 30, 2026 filing | — |
| Non-GAAP diluted net income per share non-GAAP | $4.73 | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRTX
this stock
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
|
ARGX
Argenx SE
|
$59.19B | +11.9% | — | — | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 34
Vertex said its November 30th PDUFA date for povitacicept in IgA nephropathy is on track, with high visibility and confidence. Interim phase three data from the amplitude study of anaxiplin in APOL1-mediated kidney disease are expected early in 2027. Management has talked about $500 million plus in revenue from non-CF products.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRTX | -1.9% | +2.3% | +19.9% | -4.0% | +18.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +2.0% | +7.8% | +23.3% | -0.6% | +11.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.